Royalty-based investment model could bridge ‘valley of death’ between drug discovery and delivery

A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), Questrom School of Business at Boston University, and QLS Advisors have introduced a new approach to funding clinical trials for amyotrophic lateral sclerosis (ALS) therapies.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup